Does Semax cause hair loss?
Hair loss has not been documented as a side effect of Semax in any published clinical trials, animal studies, or formal safety reports. However, absence of evidence is not evidence of absence—this question deserves a thorough answer, not simple dismissal.
Concerns about Semax and hair loss circulate mainly within online nootropic communities. A small number of users have reported increased hair loss during or after using Semax. These are anecdotal reports—personal observations rather than controlled scientific data—that cannot be verified. However, they appear frequently enough to warrant serious consideration.
No peer-reviewed study has listed hair loss as an adverse effect of Semax. No animal studies have reported hair thinning, follicle damage, or alopecia following Semax administration. No clinical trials—in patients with stroke, cerebrovascular insufficiency, optic nerve diseases, or motor neuron disease—have mentioned hair loss as a reported complaint [1], [2], [3]. A review of 15 years of Semax development, summarizing decades of Russian clinical use, did not list hair loss among any observed side effects [4].
This is a significant omission. However, it should be noted that none of these studies were specifically designed to monitor hair loss, and short clinical courses may not capture delayed effects on the hair follicle cycle.
How often does hair loss occur with Semax?
Based on published scientific literature, the frequency of hair loss associated with Semax use is unknown and has never been systematically measured. The only available information comes from anecdotal reports from online users, and even then, these reports are relatively rare compared to the overall number of shared experiences.
Hair loss is also a very common condition in the general population. Androgenetic alopecia — male or female pattern hair loss, genetically and hormonally determined — affects a significant portion of adults regardless of the use of any peptides. This makes it difficult to determine whether hair loss during Semax use is causally related to the peptide, is a coincidence, or is simply the natural progression of pre-existing baldness.
The reliable answer is that the scientific literature cannot tell us how often this side effect occurs because it has never been studied. The lack of signals in published clinical data provides some reassurance—but it does not rule out the possibility that the phenomenon affects a small group of sensitive individuals.
What are users reporting about Semax and hair loss?
User reports regarding Semax and hair loss extend beyond peer-reviewed scientific literature and cannot be assessed in the same way as clinical data. Reports from online nootropic communities describe a pattern where some users notice increased hair loss—typically describing more hair in the shower drain or on their pillow—starting a few weeks after beginning Semax. Some report the shedding stops after discontinuing Semax. Others report it resolves spontaneously with continued use. A smaller number describe persistent thinning they attribute to Semax.
These correlations do not prove causation, and there are several alternative explanations for each case. Stress-induced hair loss, medically known as telogen effluvium, is very common and can be triggered by any physical or psychological change. Changes in BDNF levels during Semax use could theoretically impact the hair follicle cycle—this is discussed in detail in Section 6.2. Changes in diet or sleep often accompany nootropics users' self-optimization practices. Confirmation bias—the tendency to attribute an observed change to a recently added factor—may also lead users to blame Semax for hair loss with a completely different cause.
None of these caveats mean that user reports should be dismissed. They represent real experiences that are worth taking seriously—however, they cannot be treated as the equivalent of clinical evidence.
What is the biological reason why Semax might affect hair?
The most biologically plausible reason why Semax might affect hair growth is its potent increase in BDNF—brain-derived neurotrophic factor. BDNF plays a documented and complex role in the hair follicle growth cycle, though this relationship requires significant caveats.
It needs to be clearly stated: the relationship between Semax and hair loss via BDNF is a theoretical biological mechanism based on separate lines of evidence — not a directly proven causal chain. No study has simultaneously measured Semax administration, BDNF changes in the scalp, and hair follicle response in the same experiment.
BDNF is not just a brain chemical. It is also present in hair follicles and actively regulates the hair growth cycle. Studies have shown that BDNF and its receptor TrkB are present in human and animal hair follicles, and that BDNF signaling is involved in the transition between the active growth phase—called anagen—and the regression phase—called catagen [5]. Some studies suggest that elevated BDNF may promote the transition from the growth phase to the regression phase under specific experimental conditions, which would theoretically lead to increased hair loss. This would be a transient phenomenon, not permanent follicle destruction. This forms the biological basis for the theoretical concern.
What is the relationship between BDNF and hair loss?
The role of BDNF in the hair follicle cycle is real, but complex. Elevated BDNF does not automatically mean hair loss in all contexts. To understand this issue, a brief explanation of the hair growth cycle is helpful.
Hair grows in repeating cycles consisting of three main phases. The anagen phase is the active growth phase, lasting several years. The catagen phase is a short transitional and regressive phase lasting a few weeks, during which the hair follicle shrinks and growth stops. The telogen phase is a resting and shedding phase, lasting a few months, during which the old hair falls out and the follicle prepares for a new cycle.
BDNF signaling through TrkB receptors has been identified in follicle cells during these phases of the cycle. If the significant increase in BDNF by Semax—including the 8-fold increase in BDNF mRNA observed in glial cell cultures [6] and the 1.4-fold increase in BDNF protein in the hippocampus [7]—extends to scalp tissue and hair follicles, it could theoretically accelerate the transition from the active growth phase to the shedding phase in follicles nearing the end of their growth phase.
However, there are a few important caveats. First, the increases in BDNF documented in studies of Semax were primarily measured in brain tissue after nasal administration, which delivers the peptide directly to the central nervous system via the olfactory pathway.
Secondly, the role of BDNF in hair follicles requires a delicate balance. The net effect likely depends on the current follicle cycle phase, the magnitude of the BDNF change, and individual biological variability.
Thirdly, even if there were temporary hair loss due to an accelerated follicle cycle, it would be a shift in time rather than destruction of the follicles, meaning a temporary and reversible phenomenon, not permanent hair loss.
Does Semax affect DHT?
No published studies have measured the effect of Semax on dihydrotestosterone — DHT for short — the androgen most directly responsible for androgenic alopecia, also known as male or female pattern baldness. DHT is produced from testosterone by an enzyme called 5-alpha-reductase and gradually shrinks hair follicles in genetically susceptible individuals.
Semax is classified as a non-hormonal peptide—it does not stimulate the production of testosterone, estrogen, or adrenal hormones [8]. There is no known mechanism by which Semax could increase DHT production or follicle sensitivity to DHT. Semax's interactions with melanocortin receptors do not involve androgen receptor pathways, and its metabolic effects do not include documented changes in testosterone or DHT metabolism.
Lack of steroidogenic activity – confirmed from the earliest pharmacological characterization of Semax [8] – makes the DHT-dependent mechanism of hair loss pharmacologically unlikely based on current knowledge. If Semax affects hair in some individuals, the DHT pathway is unlikely to be the explanation.
Is the link between Semax and hair loss proven?
No — the link between Semax and hair loss is not proven. It remains a theoretical possibility based on: anecdotal user reports, which cannot be verified; a biologically plausible but unproven mechanism regarding BDNF's role in the hair follicle cycle; and the general principle that any compound significantly altering growth factor levels could theoretically affect many tissues in which those factors play regulatory roles.
There is a lack of direct evidence. A study measuring BDNF levels in hair follicles after Semax administration has never been conducted. A controlled observation of the rate of hair loss in Semax users compared to non-users has never been published. A case series documenting the onset of hair loss, its resolution after discontinuation, and the exclusion of alternative causes has never been formally described in the scientific literature.
Until such evidence emerges, the question of hair loss should be classified as an unresolved issue rather than an established side effect.
How to prevent hair loss while using Semax?
There is no evidence-based protocol for preventing hair loss during Semax use, as the effect itself has not been clinically confirmed. However, reasonable precautions can be proposed based on general principles and available pharmacological knowledge.
Before starting Semax, individuals already experiencing hair thinning or with a strong family history of baldness should be aware they may be more susceptible to any factor—including theoretical changes in the hair follicle cycle related to BDNF—that could accelerate an existing tendency toward hair loss. Careful documentation of hair status prior to initiating a new compound provides a useful baseline.
Using the lowest effective dose for the shortest possible time is a reasonable rule of thumb for any compound with incompletely characterized side effects. In Russian clinical practice, Semax is typically used in specific 10-day courses, rather than continuously and indefinitely. This cyclical approach may reduce the likelihood of cumulative effects on BDNF signaling in follicles, if such effects exist.
Maintaining good nutritional status—particularly adequate protein, iron, zinc, and biotin, which are essential for healthy hair growth—provides a biological buffer against hair loss from any cause. Stress management is equally important, as telogen effluvium—stress-induced, temporary hair loss—is one of the most common causes of sudden diffuse hair shedding and can be easily mistaken for a compound-specific effect.
What to do if you notice hair loss while using Semax?
If you notice increased hair loss while using Semax, the most reasonable first step is to thoroughly evaluate other possible causes before attributing the change to Semax. Ask yourself: Have you been under exceptional stress recently? Have you changed your diet, sleep, or other supplements? Are you a man at an age when androgenetic alopecia naturally begins? Does anyone in your family experience similar hair loss at a similar age?
If alternative causes seem unlikely, and the shedding clearly correlates with Semax use, a reasonable approach is to discontinue Semax and observe if the shedding subsides within 2–3 months. Telogen effluvium—whether triggered by Semax or another factor—typically resolves within 3–6 months after the trigger is removed.
Consultation with a dermatologist or physician is the most medically justified approach. A specialist can examine your hair loss pattern, order blood tests to rule out thyroid abnormalities, iron deficiency, and hormonal imbalances, and perform a scalp analysis. A professional assessment provides objective data, not subjective self-assessment. They can also determine if the hair loss pattern is consistent with diffuse effluvium—which a BDNF-dependent mechanism would predict, causing widespread shedding across the scalp—or with androgenetic alopecia, which would indicate an underlying genetic predisposition.
Does stopping Semax reverse hair loss?
Based on the proposed theoretical mechanism—transient acceleration of the hair follicle cycle by BDNF changes—hair loss induced by Semax, if it occurs, should be transient and reversible after discontinuation. Telogen effluvium is characterized by diffuse shedding caused by premature follicle cycling, rather than their destruction or miniaturization—a process by which follicles gradually shrink in androgenetic alopecia. This type of shedding is typically fully reversible after removal of the triggering factor, with normal hair density usually being restored within 3–6 months.
Some online users have reported that hair loss stopped after discontinuing Semax, which aligns with the expected pattern. However, these reports do not confirm that Semax was indeed the cause, rather than a coincidental resolution of a stress-related shedding episode.
Permanent hair loss caused by Semax is not a documented outcome in any published study. There is no known biological mechanism by which Semax would permanently destroy or miniaturize hair follicles.
However, one important caveat should be noted. In individuals with existing androgenetic alopecia, any episode of accelerated hair loss from any cause can suddenly reveal the previously existing miniaturization process. This can be perceived as permanent hair loss, even if the acute phase of shedding subsides, because the previously subtle thinning now becomes more apparent.
What alternatives to Semax can reduce the risk of hair loss?
No peptide has been specifically studied as an alternative to Semax that is devoid of the risk of hair loss, as the association of Semax with hair loss itself is not yet established. If the primary concern is the theoretical mechanism of BDNF, compounds that induce smaller or more targeted increases in BDNF could theoretically be associated with lower risk via that particular pathway.
Selank, a related synthetic peptide with partly overlapping cognitive effects, has a different primary mechanism of action. It acts primarily by reducing anxiety through GABA modulation, rather than through a pronounced increase in BDNF. This means it does not induce the same degree of BDNF increase as Semax, which could theoretically make it less likely to impact the follicle cycle via this pathway. However, this reasoning is purely speculative and should not be presented as evidence-based guidance.
The simplest approach for someone truly concerned about hair loss is to discontinue Semax, wait at least 2-3 months to assess if the observed changes subside, and consult with a doctor to determine what is actually happening—before making any decisions about alternative compounds. Switching to another nootropic peptide without first identifying and confirming the actual cause of hair loss offers no guarantee of avoiding the problem, as the cause may be entirely unrelated to Semax.
Disclaimer
This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or claim regarding the safety or efficacy of Semax for treating any medical condition. Semax remains an investigational compound in most countries worldwide, including the United States and most European countries, and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article is derived from preclinical animal studies and a limited number of human clinical trials. Additional, well-designed clinical studies are necessary to more accurately establish the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans. Any individual considering the use of any investigational peptides should consult with a qualified healthcare professional.
References
Gusev, E. I., Skvortsova, V. I., & Chukanova, E. I. (2005). Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Journal of Neurology and Psychiatry named after S.S. Korsakov, 105(2), 35–40. PMID: 15792140
[2] Serdiuk, A. V., Levitskiĭ, G. N., Miasoedov, N. F., & Skvortsova, V. I. (2007). The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Journal of Neurology and Psychiatry named after S.S. Korsakov, 107(4), 29–39. PMID: 18379501
[3] Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Sheremet, N. L., & Andreeva, L. A. (2000). Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Ophthalmology Journal, 116(1), 15–18. PMID: 10741256
[4] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745
[5] Rahman, O. F., Lee, S. J., & Seeds, W. A. (2026). Therapeutic peptides in orthopaedics: Applications, challenges, and future directions. Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews, 10(1), e25.00236. https://doi.org/10.5435/JAAOSGlobal-D-25-00236
Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
Hormonal activity of the ACTH(4-10) analog — a prolonged-action stimulant of learning. Bulletin of Experimental Biology and Medicine, 101(3), 267–268. PMID: 3006824